These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 36006442)

  • 1. HER2 status is positively associated with vessel invasion of colorectal cancer: a retrospective large cohort study.
    Wang M; Wang X; Li Y; Li Q; Cai S; Li X; Ma M
    Int J Colorectal Dis; 2022 Sep; 37(9):2061-2067. PubMed ID: 36006442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer.
    He C; Bian XY; Ni XZ; Shen DP; Shen YY; Liu H; Shen ZY; Liu Q
    World J Gastroenterol; 2013; 19(14):2171-8. PubMed ID: 23599643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Death decoy receptor overexpression and increased malignancy risk in colorectal cancer.
    Zong L; Chen P; Wang DX
    World J Gastroenterol; 2014 Apr; 20(15):4440-5. PubMed ID: 24764685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer.
    Sartore-Bianchi A; Amatu A; Porcu L; Ghezzi S; Lonardi S; Leone F; Bergamo F; Fenocchio E; Martinelli E; Borelli B; Tosi F; Racca P; Valtorta E; Bonoldi E; Martino C; Vaghi C; Marrapese G; Ciardiello F; Zagonel V; Bardelli A; Trusolino L; Torri V; Marsoni S; Siena S
    Oncologist; 2019 Oct; 24(10):1395-1402. PubMed ID: 30952821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HER2 as a potential biomarker guiding adjuvant chemotherapy in stage II colorectal cancer.
    Feng Y; Li Y; Huang D; Cai S; Peng J
    Eur J Surg Oncol; 2019 Feb; 45(2):167-173. PubMed ID: 30420187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.
    Sartore-Bianchi A; Trusolino L; Martino C; Bencardino K; Lonardi S; Bergamo F; Zagonel V; Leone F; Depetris I; Martinelli E; Troiani T; Ciardiello F; Racca P; Bertotti A; Siravegna G; Torri V; Amatu A; Ghezzi S; Marrapese G; Palmeri L; Valtorta E; Cassingena A; Lauricella C; Vanzulli A; Regge D; Veronese S; Comoglio PM; Bardelli A; Marsoni S; Siena S
    Lancet Oncol; 2016 Jun; 17(6):738-746. PubMed ID: 27108243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lgr5 over-expression is positively related to the tumor progression and HER2 expression in stage pTNM IV colorectal cancer.
    Gao FJ; Chen JY; Wu HY; Shi J; Chen M; Fan XS; Huang Q
    Int J Clin Exp Pathol; 2014; 7(4):1572-9. PubMed ID: 24817953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of clinicopathological characteristics and prognostic factors of early-stage human epidermal growth factor receptor 2 (HER2)-low breast cancer: Compared with HER2-0 breast cancer.
    Wu Q; Yang F; Liu Y; Zhang H; Zhang S; Xin L; Xu L
    Cancer Med; 2023 Oct; 12(19):19560-19575. PubMed ID: 37772432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Association of peripheral nerve invasion with clinicopathological factors and prognosis of colorectal cancer].
    Han D; Wei Y; Wang X; Wang G; Chen Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Jan; 20(1):62-66. PubMed ID: 28105622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HER2-low-positive and response to NACT and prognosis in HER2-negative non-metastatic BC.
    Li JJ; Yu Y; Ge J
    Breast Cancer; 2023 May; 30(3):364-378. PubMed ID: 36656510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinicopathological characteristics and prognosis of different molecular types of breast cancer].
    Liu ZF; Chen C; Yao XL; Sun SR
    Zhonghua Yi Xue Za Zhi; 2016 Jun; 96(22):1733-7. PubMed ID: 27356638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HER2 overexpression/amplification status in colorectal cancer: a comparison between immunohistochemistry and fluorescence in situ hybridization using five different immunohistochemical scoring criteria.
    Sun Q; Li Q; Gao F; Wu H; Fu Y; Yang J; Fan X; Cui X; Pu X
    J Cancer Res Clin Oncol; 2023 Feb; 149(2):579-592. PubMed ID: 36018511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathological features of HER2 positive metastatic colorectal cancer and survival analysis of anti-HER2 treatment.
    Yang L; Li W; Lu Z; Lu M; Zhou J; Peng Z; Zhang X; Wang X; Shen L; Li J
    BMC Cancer; 2022 Apr; 22(1):355. PubMed ID: 35365123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of EGFR, Her2 predict lymph node metastasis (LNM)-associated metastasis in colorectal cancer.
    Lu Y; Jingyan G; Baorong S; Peng J; Xu Y; Cai S
    Cancer Biomark; 2012; 11(5):219-26. PubMed ID: 23220854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of two different HER2 scoring systems and clinical relevance for colorectal cancer.
    Liu F; Ren C; Jin Y; Xi S; He C; Wang F; Wang Z; Xu RH; Wang F
    Virchows Arch; 2020 Mar; 476(3):391-398. PubMed ID: 31720832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential prognostic value of positive HER2 status determined by immunohistochemistry or fluorescence in situ hybridization in breast cancer.
    Stocker A; Trojan A; Elfgen C; Hilbers ML; Moskovszky L; Varga Z
    Breast Cancer Res Treat; 2020 Sep; 183(2):311-319. PubMed ID: 32638236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variability in HER2 expression between primary colorectal cancer and corresponding metastases.
    Shan L; Lv Y; Bai B; Huang X; Zhu H
    J Cancer Res Clin Oncol; 2018 Nov; 144(11):2275-2281. PubMed ID: 30203148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of PTEN, VEGF, HER2 and P53 status in determining colorectal cancer benefit from bevacizumab therapy.
    Kara O; Duman BB; Kara B; Erdogan S; Parsak CK; Sakman G
    Asian Pac J Cancer Prev; 2012; 13(12):6397-401. PubMed ID: 23464465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perineural invasion is associated with poor prognosis of colorectal cancer: a retrospective cohort study.
    Cao Y; Deng S; Yan L; Gu J; Li J; Wu K; Cai K
    Int J Colorectal Dis; 2020 Jun; 35(6):1067-1075. PubMed ID: 32179991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HER2/neu testing in primary colorectal carcinoma.
    Ingold Heppner B; Behrens HM; Balschun K; Haag J; Krüger S; Becker T; Röcken C
    Br J Cancer; 2014 Nov; 111(10):1977-84. PubMed ID: 25211663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.